ARDELYX, INC.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Revenue $12.5M $1.9M $24.2M $44.7M $11.4M $5.4M
Product sales net $0 $0 $0 $0 $0
Licensing and collaboration revenue $12.5M $1.9M $24.2M $44.7M $11.4M
Non-cash royalty revenue $0 $0 $0 $0 $0
Cost of Revenue $8.4M
Gross Profit $33.6M $24.0M
Gross Margin 269.3% 99.3%
Operating Expenses
Research & Development $75.5M $94.2M $39.9M $25.9M $28.1M $10.2M
SG&A Expense $23.2M $18.7M $13.5M $7.3M $3.7M $4.0M
Operating Income $-65.1M $-112.9M $-29.4M $-1.6M $-2.9M $-8.8M
Operating Margin -522.0% -6,021.1% -121.5% -3.5% -25.0% -162.8%
Interest Expense
Pretax Income $-63.2M $-112.4M $-29.7M $-3.1M $-6.4M $-9.8M
Income Tax Expense $1.2M $-29.0K $67.0K $141.0K
Net Income $-64.3M $-112.4M $-29.6M $-3.2M $-6.6M $-9.8M
Net Margin -515.7% -5,994.0% -122.4% -7.2% -57.4% -180.9%
EPS (Basic) $-1.36 $-2.80 $-1.29 $-0.31 $-5.82 $-11.32
EPS (Diluted) $-1.36 $-2.80 $-1.29 $-0.31 $-5.82 $-11.32
Shares Outstanding (Basic) 47.5M 47.3M 26.0M 18.6M 1.2M
Shares Outstanding (Diluted) 47.5M 47.3M 26.0M 18.6M 1.2M
Dividends Per Share
← Newer Page 2 of 2 Older →